Accelerating drug development and approval

Drug News and Perspectives

Volumn 23, Issue 1, 2010, Pages 37-47

  Cole, Patrick ^a  

^a Editorial Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ARTEMETHER; AZTREONAM; BENFLUMETOL; BEVACIZUMAB; CATUMAXOMAB; CETHROMYCIN; COLCHICINE; CYCLOSPORIN A; ECULIZUMAB; EVEROLIMUS; GANCICLOVIR; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MELPHALAN; MIDAZOLAM MALEATE; MIFEPRISTONE; NALFURAFINE; OFATUMUMAB; PACLITAXEL; PERTUZUMAB; PLERIXAFOR; PRALATREXATE; ROMIDEPSIN; ROMIPLOSTIM; SOTALOL; TADALAFIL; TRYPAN BLUE; UNINDEXED DRUG; VIGABATRIN;

CHRONIC LYMPHATIC LEUKEMIA; CUSHING DISEASE; DRUG APPROVAL; DRUG CONTROL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; ENDOCRINE TUMOR; ENTERITIS; EUROPE; FAMILIAL MEDITERRANEAN FEVER; FOOD AND DRUG ADMINISTRATION; FUNDING; GOUT; GOVERNMENT; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEALTH PROGRAM; HEART ARRHYTHMIA; HEMOLYTIC UREMIC SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA VIRUS A H1N1; KERATOCONJUNCTIVITIS; KIDNEY CARCINOMA; LYMPHOMA; MALARIA; MULTIPLE MYELOMA; NEUROENDOCRINE DISEASE; NONHODGKIN LYMPHOMA; OVARY CANCER; PLAGUE; PRURITUS; PULMONARY HYPERTENSION; REVIEW; SEIZURE; STOMACH CANCER; T CELL LYMPHOMA; TULAREMIA; UNITED STATES; VIRUS ENCEPHALITIS; VIRUS KERATITIS; WEST SYNDROME;

DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; ORPHAN DRUG PRODUCTION;

EID: 77950611794     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.1.1441464     Document Type: Review

References (49)

1. Steinbrook, R. The NIH Stimulus - The Recovery Act and biomedical research. N Engl J Med 2009, 360(15): 1479-1481
2. Department of Health and Human Services. National Institutes of Health: Scientific research. Available at: http://www.hhs.gov/recovery/reports/plans/ scientific-research. pdf. Accessed November 17, 2009.
3. Department of Health and Human Services. Comparative effectiveness research funding. Available at: http://www.hhs.gov/recovery/programs/cer/index. html. Accessed November 17, 2009.
4. National Institutes of Health. Preliminary NIH ARRA FY2009 funding as of October 26, 2009. Available at: http://report.nih.gov/PDF/Preliminary-NIH-ARRA- FY2009-Funding.pdf. Accessed November 17,2009.
5. National Institutes of Health. Recovery Act news archive. Available at: http://grants.nih.gov/recovery/news-archive.html. Accessed November 17, 2009.
6. Fletcher, M. A. Obama: Stimulus Act gave biomedical research record boost. http://voices. washingtonpost.com/44/2009/09/30/obama-stimulus-act-gave- biomed.html. Washington Post online, September 30, 2009.
7. Innovative Medicines Initiative (IMI) website. http://imi.europa.eu/ index-en.html. Accessed November 17, 2009.
8. European Union. "Innovative Medicines Initiative" (IMI): €246 Million to support public-private research cooperation for a fast development of better medicines. May 18, 2009. Available at: http://europa.eu/rapid/pressReleasesAction.do?reference=IP/09/802&format= HTML&aged=0&language=EN &guiLanguage=en. Accessed November 17, 2009.
9. European Union. Innovative Medicines Initiative: Putting Europe at the forefront of biopharmaceutical innovation. September 14, 2009. Available at: http://europa.eu/rapid/pressReleasesAction.do?reference=IP/09/1310&format= HTML&aged= 0&language= EN&guiLanguage=en. Accessed November 17, 2009.
10. Innovative Medicines Initiative. IMI 2nd Call 2009. Available at: http://www.imi-europe.org/Pages/default.aspx. Accessed December 14, 2009.
11. Food and Drug Administration. Developing orphan products: FDA and Rare Disease Day. http://www.fda.gov/ForConsumers/Consumer Updates/ucm107293.htm. Accessed November 17, 2009.
12. Food and Drug Administration. FDA application search orphan drug designations and approvals. Available at: http://www.access-data.fda.gov/ scripts/opdlisting/oopd/index. cfm. Accessed November 17, 2009.
13. Food and Drug Administration. OPD Research Grants Program. Available at: http://www.fda.gov/Forlndustry/Developing ProductsforRareDiseasesConditions/Whom toContactaboutOrphanProductDevelopment /ucm134580.htm. Accessed November 17, 2009.
14. European Medicines Agency. EMEA public statement on fee reductions for designated orphan medicinal products. European Medicines Agency Public Statement February 4, 2009. Available at: http://www.emea.europa.eu/pdfs/human/comp/ 6320009en.pdf.
15. European Medicines Agency. Committee for Orphan Medicinal Products April 2009 Plenary Meeting Monthly Report. April 8, 2009. Available at: http://www.emea.europa.eu/pdfs/human/comp/pr/15916509en.pdf. Accessed December 4, 2009.
16. European Medicines Agency. Committee for Orphan Medicinal Products November 2009 Plenary Meeting Monthly Report. November 17, 2009. Available at: http://www.emea.europa.eu/pdfs/human/comp/pr/67927809 en.pdf. Accessed Decmber 4, 2009.
17. Data from Prous Science Integrity®.
18. Orphanet Report Series - List of orphan drugs in Europe. October 2009. Available at: http://www.orpha.net/orphacom/cahiers/docs/GB/list-of-orphan- drugsjn-europe. pdf.
19. Food and Drug Administration. Fast track, accelerated approval and priority review. Available at: http://www.fda.gov/ForConsumers/ByAudience/ ForPatient Advocates/SpeedingAccesstoImportant NewTherapies/ucm128291.htm. Accessed November 18, 2009.
20. Tufts Center for the Study of Drug Development. Fast track drugs reach market sooner. Tufts Center for the Study of Drug Development News Release, September 3, 2008.
21. LoRusso, P.M. Phase O clinical trials: An answer to drug development stagnation? J Clin Oncol 2009, 27(16): 2586-2588
22. Kummar, S., Doroshow, J.H., Tomaszewski, J.E. et al. Phase O clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies. Eur J Cancer 2009, 45(5): 741-746
23. Kummar, S., Kinders, R., Gutierrez, M.E. et al. Phase O clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009, 27(16): 2705-2711
24. Outcomes from EUMAPP - A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. Available at: http://www.eumapp.com. Accessed November 20, 2009.
25. Outcomes from EUMAPP - A study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. Xceleron News Release, July 13, 2009.
26. Food and Drug Administration. Critical Path Annual Report 2008. Available at: http://www.fda.gov/downloads/ScienceRes earch/SpecialTopics/ CriticalPathlnitiative/UCM186110.pdf. Accessed November 20, 2009.
27. Food and Drug Administration. Critical Path Initiative - Frequently asked questions. Available at: http://www.fda.gov/Science Research/SpecialTopics/ CriticalPathlnitiative/ucm077015.htm. Accessed November 20, 2009.
28. Food and Drug Administration. Clinical Trials Transformation Initiative, http://www.fda.gov/ScienceResearch/SpecialTopics/Critical Pathlnitiative/ SpotlightonCPIProjects/ucm 167886.htm#Partll. Accessed November 20, 2009.
29. Clinical Trials Transformation Initiative website. https://www. trialstransformation.org. Accessed November 20, 2009.
30. Food and Drug Administration. Upcoming events on CPI. CPI funding opportunities. Available at: http://www.fda.gov/downloads/ScienceResearch/ SpecialTopics/Critic alPathlnitiative/UpcomingEventsonCPI/UCM 180264.pdf. Accessed November 20, 2009.
31. Food and Drug Administration. Spotlight on CPI projects. Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/Critical Pathlnitiative/ SpotlightonCPIProjects/default.htm. Accessed November 20, 2009.
32. World Health Organization. Neglected tropical diseases. Available at: http://whqlibdoc.who.int/publications/2009/9789241598705-eng.pdf. Accessed November 23, 2009.
33. Grabowski, H.G., Ridley, D.B., Moe, J.L Priority review vouchers to encourage innovation for neglected diseases. http://prvinfo.org/files/ grabowski%20et%20al%202008 %20manuscript.pdf. Accessed November 23, 2009.
34. Kesselheim, A.S. Drug development for neglected diseases - The trouble with FDA review vouchers. N Engl J Med 2008, 359(19): 1981-3.
35. Food and Drug Administration. Guidance for Industry - Tropical Disease Priority Review Vouchers. October 2008. Available at: http://www.fda.gov/OHRMS/ DOCKETS/98fr/FDA-2008-D-0530-gdl.pdf. Accessed November 23, 2009.
36. FDA approves Coartem tablets to treat malaria. FDA News Release, April 8, 2009.
37. Anderson, T. Novartis under fire for accepting new reward for old drug. Lancet 373(9673): 1414.
38. von Schaper, E. Novartis, Sanofi sales unleashed by FDA disease plan. http://www.bloomberg.com/apps/news?pid=newsarchive &sid=a3s7BIVbcMLs. Accessed November 23, 2009.
39. National Institutes of Health. NIH announces new program to develop therapeutics for rare and neglected diseases. May 20, 2009. https://www. rarediseases.info.nih.gov/files/TRND%20Press%20Release.pdf. Accessed November 23, 2009.
40. U.S. Department of Health and Human Services. HHS 2009 H1N1 vaccine development activities. Available at: https://www.medicalcountermeasures.gov/ BARDA/MCM/panflu/factsheet.aspx. Accessed December 4, 2009.
41. Food and Drug Administration. Letter from the Commissioner to nation's healthcare professionals on H1N1 vaccine. November 10, 2009. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm189691.htm. Accessed December 4, 2009.
42. Food and Drug Administration. Influenza A (H1N1) 2009 monovalent. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm181950. htm. Accessed December 4, 2009.
43. When and how much of the 2009 H1N1 vaccine will be available? http://answers.flu.gov/questions/4967. Accessed December 4, 2009.
44. WHO declares influenza pandemic - European Medicines Agency initiates crisis-management plan. EMEA Press Release, June 12, 2009.
45. European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009. EMEA Press Release, September 25, 2009.
46. European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (H1N1) 2009. EMEA Press Release, October 2, 2009.
47. European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines. EMEA Press Release, November 20, 2009.
48. European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the Marketing Authorisation Application for a pandemic influenza vaccine. September 25, 2009. Available at: http://www.emea.europa.eu/pdfs/human/pandemicinfluenza/35938109en. pdf. Accessed December 4, 2009.
49. European Medicines Agency. European strategy for influenza A/H1N1 vaccine benefit-risk monitoring. October 2009. Available at: http://www.emea.europa.eu/ pdfs/human/pandemicinfluenza/european-strategy.pdf. Accessed December 4, 2009.